NDC 51662-1239-2 - NALOXONE HYDROCHLORIDE
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 51662-1239
- Requested NDC
- 51662-1239-2
- Package NDCs from labels
- 51662-1239-1, 51662-1239-2, 51662-1239-3
- Manufacturer
- HF Acquisition Co. LLC, DBA HealthFirst
- Effective date
- 2024-01-25
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| NALOXONE HYDROCHLORIDE - HF Acquisition Co. LLC, DBA HealthFirst | HF Acquisition Co. LLC, DBA HealthFirst | 2024-01-25 | HUMAN PRESCRIPTION DRUG LABEL |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 51662-1239-1 | 2020-02-07 | C162847 | 48780-1 | 9d75b9d0-0c01-f424-e053-dadaa90a57ce | NALOXONE HYDROCHLORIDE INJ., USP (1mg/mL) 2mL SYR |
| 51662-1239-1 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-0c01-f424-e053-dadaa90a57ce | NALOXONE HYDROCHLORIDE INJ., USP (1mg/mL) 2mL SYR |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 51662-1239-1 | NALOXONE HYDROCHLORIDE | 2 mL in 1 SYRINGE, PLASTIC | INJECTION | 2 | 6 | |
| 51662-1239-1 | NALOXONE HYDROCHLORIDE | 1 in 1 BOX | INJECTION | 1 | 6 | |
| 51662-1239-2 | NALOXONE HYDROCHLORIDE | 1 mL in 1 POUCH | INJECTION | 1 | 6 | |
| 51662-1239-3 | NALOXONE HYDROCHLORIDE | 10 in 1 CASE | INJECTION | 10 | 6 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 51662-1239 | NALOXONE HYDROCHLORIDE INJECTION [HF ACQUISITION CO. LLC, DBA HEALTHFIRST] | 6 | Current NDC, Legacy NDC, 4 package rows | 20240126_74fc593e-ed47-efae-e053-2991aa0a5997.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | Amneal Pharmaceuticals LLC | 8091a73d-9ecd-4578-a57b-5d85a2c5a16a | 2026-08-25 | Warnings | F850569PQR |
| NARCAN | NALOXONE HYDROCHLORIDE NASAL | Emergent Devices Inc. | a0ebc83d-2892-40de-bc0a-775ce90b30db | 2026-08-17 | Warnings | F850569PQR |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | Sportpharm LLC | 3750bf77-342c-4469-8bbb-f71009aa03fa | 2026-07-02 | Warnings | F850569PQR |
| Naloxone Hydrochloride | NALXONE HYDROCHLORIDE | Civica, Inc. | 21d20dff-6efe-481e-a5a0-9c80ded73ca9 | 2026-06-30 | Warnings, Adverse reactions | F850569PQR |
| BUPRENORPHINE AND NALOXONE | BUPRENORPHINE AND NALOXONE | Ascend Laboratories, LLC | 2e807ed0-6df3-47b5-b7ee-b421c5bf0aa7 | 2026-06-29 | Warnings, Adverse reactions | F850569PQR |
| Pentazocine and naloxone | PENTAZOCINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | Actavis Pharma, Inc. | a28450a0-ac93-4235-b9a6-58cdf24773cb | 2026-06-19 | Boxed warning, Warnings, Adverse reactions | F850569PQR |
| Zubsolv | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | Edenbridge Pharmaceuticals LLC. | 57583c1d-9c44-4503-917d-68dba7377bd1 | 2026-06-12 | Warnings, Adverse reactions | F850569PQR |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | HF Acquisition Co LLC, DBA HealthFirst | 53ed164c-dd09-4ea4-e063-6294a90a2434 | 2026-06-11 | Warnings, Adverse reactions | 1191250 F850569PQR |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | A-S Medication Solutions | 5906381c-81f4-4635-867a-e56e4d629692 | 2026-06-03 | Warnings, Adverse reactions | F850569PQR |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | Hospira, Inc. | 8535cc84-ad4a-4d67-8480-fb5a2e3406f8 | 2026-05-27 | Warnings, Adverse reactions | F850569PQR |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | Somerset Therapeutics, LLC | dfa48492-d83b-48cc-9ad1-bdc0c2ac9931 | 2026-05-05 | Warnings, Adverse reactions | F850569PQR |
| NARCAN | NALOXONE HYDROCHLORIDE NASAL | Sportpharm LLC | 3d43b2a2-9cc3-4c14-8ae7-fea4c83a7f92 | 2026-04-24 | Warnings | F850569PQR |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Redpharm Drug | 5005a6c8-9a3b-a99a-e063-6294a90aac13 | 2026-04-22 | Warnings, Adverse reactions | F850569PQR |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Aveva Drug Delivery Systems Inc. | cb112448-49a1-4209-bcdb-7cfae6501f51 | 2026-04-07 | Warnings, Adverse reactions | F850569PQR |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | BluePoint Laboratories | 327004b0-560a-84d0-e063-6294a90aa743 | 2026-04-02 | Warnings | F850569PQR |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | INGENUS PHARMACEUTICALS, LLC | 4951ec29-609b-4836-b0e4-0d9c1d6ae6fe | 2026-03-23 | Warnings, Adverse reactions | F850569PQR |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | HF Acquisition Co. LLC. DBA HealthFirst | 4d66b96a-acbb-2292-e063-6294a90af788 | 2026-03-19 | Warnings, Adverse reactions | F850569PQR |
| REZENOPY | NALOXONE HCL | Scienture LLC | 5bb502aa-014f-4a36-8972-42a9439168fe | 2026-03-03 | Warnings, Adverse reactions | F850569PQR |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | Henry Schein, Inc | bd65e3fe-cd7a-4855-8f55-8cc3a0921ccc | 2026-03-02 | Warnings, Adverse reactions | ANDA072076 1191250 F850569PQR |
| Buprenorphine and Naloxone | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | PAI Holdings, LLC dba PAI Pharma | d5b011ef-f1be-47f2-8f8b-07553f36193c | 2026-02-28 | Warnings, Adverse reactions | F850569PQR |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.